The case for & against
Bull & Bear analysis
Bearish
Alder BioPharmaceuticals, Inc. was a biopharmaceutical company specializing in the development of treatments for neurological disorders, particularly its lead candidate, eptinezumab, which targeted migraine prevention. The company was notably acquired by H. Lundbeck A/S in September 2019, which reflects its innovative position in the biopharmaceutical space. This acquisition halted Alder's operations as an independent public entity, emphasizing the competitive landscape and strategic moves within the pharmaceutical industry.
Bull says
- ↑Lundbeck acquired Alder for up to $1.95B at $18/share
- ↑Eptinezumab’s potential EU approval opens large migraine market
- ↑Chronic migraine prevention demand drives long-term growth outlook
- ↑High earnings yield and strong ROE support attractive valuation
- ↑Healthy profitability and robust free cash flow enable reinvestment
- ↑Positive momentum technical factors indicate favorable share performance
Bear says
- ↓Post-merger integration may shift resource allocation and execution
- ↓Multiple established migraine therapies threaten eptinezumab’s pricing power
- ↓EU regulatory approval delays could significantly hinder revenue
- ↓Limited disclosure under Lundbeck reduces investor visibility
- ↓Negative sales growth forecast for next fiscal year signals headwinds
- ↓Elevated volatility and liquidity concerns may deter investors